Saturday 17 October 2026
Export MXCT’s income statement to Excel — free account
MaxCyte, Inc.
MXCT Healthcare Medical Devices
MaxCyte, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $33.0 million, down 14.5% from fiscal 2024. In the quarter to June 2026, revenue fell 14.5%, EPS grew 33.3% and free cash flow grew 54.7%, each against the same quarter a year earlier.
1.30
0.00
0.00%
Follow MXCT
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
4.89 | 5.00 | 2.32 | 4.23 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(22.59) | (61.35) | (9.16) | (28.19) | |
P/B ratio |
0.93 | 0.96 | 0.45 | 0.83 | |
Price to Tangible BV |
0.96 | 0.97 | 0.45 | 0.83 | |
EV/Sales |
1.97 | 2.02 | (0.84) | 0.99 | |
EV/EBITDA |
0.00 | 0.00 | 0.68 | 0.00 | |
EV/Operating CF |
(1.71) | (1.94) | 0.96 | (1.33) | |
EV/FCF |
(1.64) | (1.85) | 0.92 | (1.30) | |
Quick Ratio |
7.08 | 7.47 | 10.88 | 11.08 | |
Current Ratio |
7.74 | 8.30 | 12.04 | 12.26 | |
Net Debt/EBITDA |
7.53 | 14.66 | 19.17 | 11.48 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.15 | 0.15 | 0.15 | 0.15 | |
Operating CF/Net income |
0.60 | 0.28 | 1.72 | 0.53 | |
Capex/Depreciation |
(2.73) | (0.05) | (0.36) | (0.06) | |
Research and Development Expense of Revenue |
77.84% | 45.68% | 39.96% | 58.49% | |
Selling, General and Administrative Expense of Revenue |
145.91% | 123.10% | 97.34% | 146.09% | |
Intangible Assets out of Total Assets |
0.02 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
28.61% | 9.67% | 11.82% | 15.95% | |
Graham Net Nets |
0.54 | 0.53 | 1.29 | 0.73 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(27.85%) | (27.74%) | (52.86%) | (26.83%) | |
Free Cash Flow Yield |
(24.47%) | (21.93%) | (39.24%) | (17.99%) | |
Revenue per Share |
0.06 | 0.07 | 0.09 | 0.07 | |
Operating CF per Share |
(0.07) | (0.03) | (0.08) | (0.04) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.07) | (0.03) | (0.08) | (0.04) | |
Cash per Share |
0.99 | 0.97 | 1.00 | 0.99 | |
Shareholders Equity per Share |
1.69 | 1.61 | 1.57 | 1.49 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.69 | 1.61 | 1.57 | 1.49 | |
Free Cash Flow |
(7.76) | (2.92) | (8.39) | (4.72) | |
Working Capital |
108.54 | 104.10 | 112.73 | 111.38 | |
Capital Expenditures |
(0.30) | (0.23) | (0.22) | (0.06) | |
Net Current Asset Value |
91.44 | 87.35 | 96.35 | 95.35 | |
EV/EBIT |
0.00 | 0.00 | 0.59 | 0.00 | |
Capex to Sales |
0.04 | 0.03 | 0.02 | 0.01 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
6.43 | 4.09 | 4.89 | 4.84 | |
Average Payables |
1.58 | 1.38 | 1.74 | 1.47 | |
Average Inventory |
9.00 | 8.23 | 7.95 | 7.87 | |
Average Assets |
231.04 | 220.99 | 212.22 | 202.21 | |
Average Common Equity |
196.79 | 188.87 | 183.65 | 174.74 |
Columns are period end dates